微创与开放中央胰腺切除术的系统综述与荟萃分析
该系统综述与荟萃分析纳入41项研究、1,004例患者,比较微创与开放中央胰腺切除术的术后结局,重点为术后胰瘘。总体胰瘘率14%、主要并发症率14%、30天死亡率1%;微创与开放两组的胰瘘、主要并发症及新发糖尿病无显著差异,微创组输血更少、外分泌功能不全更少、再入院更少。
要点
- 微创与开放中央胰腺切除术的术后胰瘘、主要并发症及新发糖尿病无显著差异。
- 微创组输血更少、外分泌功能不全更少、再入院更少。
- 在合适患者与有经验术者手中,微创可作为开放手术的安全替代。
核心结论
- 在合适患者与有经验术者手中,微创中央胰腺切除术是开放中央胰腺切除术治疗胰颈与胰体良性及低度恶性病变的安全替代方案。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Cochrane Register、Embase和Google Scholar至2021年6月1日,纳入41项研究共1,004例患者(腹腔镜微创158例、机器人辅助微创80例、开放766例),方案前瞻注册于PROSPERO(CRD42021259738),采用随机效应模型进行元回归。
主要发现
- 总体术后胰瘘率14%、主要并发症率14%、30天死亡率1%。
- 微创与开放的术后胰瘘率分别为17%与24%(P = .194),主要并发症率分别为17%与14%(P = .672),新发糖尿病率分别为3%与6%(P = .353),均无显著差异。
- 微创中央胰腺切除术相比开放手术与更少输血、更少外分泌胰腺功能不全及更少再入院相关。
- 随机效应模型元回归显示微创与开放比较:术后胰瘘为0.16[0.10; 0.24](P = .789),主要并发症为0.20[0.15; 0.25](P = .410),新发糖尿病为0.04[0.02; 0.07](P = .651)。
临床怎么用
- 对于胰颈与胰体良性及低度恶性病变的合适患者,在有经验的术者手中可考虑微创中央胰腺切除术作为开放手术的替代。
- 术后管理应重点关注术后胰瘘以及内分泌与外分泌功能不全。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This systematic review and meta-analysis aimed to give an overview on the postoperative outcome after a minimally invasive (ie, laparoscopic and robot-assisted) central pancreatectomy and open central pancreatectomy with a specific emphasis on the postoperative pancreatic fistula. For benign and low-grade malignant lesions in the pancreatic neck and body, central pancreatectomy may be an alternative to distal pancreatectomy. Exocrine and endocrine insufficiency occur less often after central pancreatectomy, but the rate of postoperative pancreatic fistula is higher. METHODS: An electronic search was performed for studies on elective minimally invasive central pancreatectomy and open central pancreatectomy, which reported on major morbidity and postoperative pancreatic fistula in PubMed, Cochrane Register, Embase, and Google Scholar until June 1, 2021. A review protocol was developed a priori and registered in PROSPERO as CRD42021259738. A meta-regression was performed by using a random effects model. RESULTS: Overall, 41 studies were included involving 1,004 patients, consisting of 158 laparoscopic minimally invasive central pancreatectomies, 80 robot-assisted minimally invasive central pancreatectomies, and 766 open central pancreatectomies. The overall rate of postoperative pancreatic fistula was 14%, major morbidity 14%, and 30-day mortality 1%. The rates of postoperative pancreatic fistula (17% vs 24%, P = .194), major morbidity (17% vs 14%, P = .672), and new-onset diabetes (3% vs 6%, P = .353) did not differ significantly between minimally invasive central pancreatectomy and open central pancreatectomy, respectively. Minimally invasive central pancreatectomy was associated with significantly fewer blood transfusions, less exocrine pancreatic insufficiency, and fewer readmissions compared with open central pancreatectomy. A meta-regression was performed with a random effects model between minimally invasive central pancreatectomy and open central pancreatectomy and showed no significant difference for postoperative pancreatic fistula (random effects model 0.16 [0.10; 0.24] with P = .789), major morbidity (random effects model 0.20 [0.15; 0.25] with P = .410), and new-onset diabetes mellitus (random effects model 0.04 [0.02; 0.07] with P = .651). CONCLUSION: In selected patients and in experienced hands, minimally invasive central pancreatectomy is a safe alternative to open central pancreatectomy for benign and low-grade malignant lesions of the neck and body. Ideally, further research should confirm this with the main focus on postoperative pancreatic fistula and endocrine and exocrine insufficiency.
引用
- Farrarons SS, van Bodegraven EA, Sauvanet A, et al. Minimally invasive versus open central pancreatectomy: Systematic review and meta-analysis. Surgery. 2022. PMID: 35987787. doi:10.1016/j.surg.2022.06.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。